Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
$358,924R01FY2023CANIH
University Of California-Irvine, Irvine CA
Investigators
Linked publications, trials & patents
Paper 39088329Paper 39035202Paper 38820140Paper 38730427Paper 38663406Paper 38572955Paper 38211590Paper 37551952Paper 36897958Paper 36658237Paper 36402738Paper 36357700Paper 36058806Paper 35546150Paper 35419306Paper 35313938Paper 35302839Paper 35027451Paper 35022322Paper 34999097Trial NCT07053007Trial NCT05334329
View original record on NIH RePORTER →